

PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

1st December 2020

Paradigm to present at the 3rd Annual Evercore ISI HealthCONx Conference

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce CEO, Paul Rennie, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference. The presentation will be a Q&A style format led by one of Evercore's healthcare analysts.

Event: 3rd Annual Evercore HealthCONx Conference

Presenting: Paul Rennie, CEO

Time: US: Thursday 3rd December, 8:25am (Eastern Time)

AUS: Friday 4th December, 12:25am (AEDT)

The event is free, with investors able to register online to view the presentation here:

<https://wsw.com/webcast/evercore11/par.ax/2640450>

A replay of the presentation will be available via the same link for a limited period following the event.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Executive Chairman.

To learn more about Paradigm Biopharmaceuticals please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com